Promising role for mesenchymal stromal cells in coronavirus infectious disease-19 (COVID-19)-related severe acute respiratory syndrome?
Fecha
2020Autor
Hamdan, Hamdan
Hashmi, Shahrukh K.
Lazarus, Hillard
Gale, Robert Peter
Qu, Wenchun
El Fakih, Riad
Documentos PDF
Imagenes y Videos
Resumen
Mesenchymal stromal cells (MSC) have immune regulatory and tissue regenerative
properties. MSCs are being studied as a therapy option for many inflammatory and
immune disorders and are approved to treat acute graft-versus-host disease (GvHD).
The severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) pandemic and
associated coronavirus infectious disease-19 (COVID-19) has claimed many lives.
Innovative therapies are needed. Preliminary data using MSCs in the setting of acute
respiratory distress syndrome (ARDS) in COVID-19 are emerging. We review
mechanisms of action of MSCs in inflammatory and immune conditions and discuss a
potential role in persons with COVID-19.
Palabras clave
Mesenchymal stromal cell; SARS-CoV2; COVID-19Enlace al recurso
https://doi.org/10.1016/j.blre.2020.100742Colecciones
Estadísticas Google Analytics
Comentarios
Respuesta Comentario Repositorio Expeditio
Gracias por tomarse el tiempo para darnos su opinión.